Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial
Ralf‐Dieter Hofheinz(University of Mannheim), Andreas Hochhaus(Jena University Hospital), Stefan Post(University of Mannheim), Axel Matzdorff(cts CaritasKlinikum Saarbrücken), Deniz Gencer(Heidelberg University), U. Hieber(University of Mannheim), Markus Moehler(Johannes Gutenberg University Mainz), Elisabeth Fritz(Gemeinschaftsklinikum Mittelrhein), Hartmut Link(Medizinische Hochschule Hannover), E. Kettner(University Hospital Magdeburg), Stephan Laechelt(University Children's Hospital Tübingen), Martina Grunewald(Institut für Bodenkultur und Pflanzenbau), Stephan Kremers, Lothar Müller, Matthias Hipp(University Hospital Regensburg), Hans Walter Lindemann(Katholisches Krankenhaus St. Johann Nepomuk), Peter Kienle(Heidelberg University), Jörg T. Hartmann(University of Tübingen), G. Hartung, Iris Burkholder(German Cancer Research Center), Frederik Wenz(University Medical Center Freiburg)
Cited by 505
Related Papers
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
|Leukemia|2022|3.8k
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
|New England Journal of Medicine|2021|1.7k